Market Research Logo

Acne Vulgaris: Opportunity Analysis and Forecasts to 2026

Acne Vulgaris: Opportunity Analysis and Forecasts to 2026

Summary


Acne vulgaris (acne) is currently one of the most common and well-established dermatology conditions, affecting around 90% of the world’s population at some point in their lifetime. The disease is a chronic, inflammatory dermatological condition of the pilosebaceous gland of the skin with a multifactorial pathogenesis. It is usually initiated during puberty by hormonal changes and further exacerbated by genetic factors.

GlobalData estimates the 2016 global acne therapeutic sales to total approximately $2.9 billion across the seven major pharmaceutical markets (7MM) covered within this report: the US, France, Germany, Italy, Spain, UK, and Japan. The US contributes 90% of these sales, generating an estimated $2.6 billion in 2016. The 5EU generated $219M in sales, with Germany being the largest market, accounting for an estimated $62.4M in sales in 2016.

By the end of the forecast period in 2026, acne sales are forecast to reach over $4.1 billion, growing at a compound annual growth rate (CAGR) of 3.5% over the 10-year forecast period. The majority of sales will come from the US, which will maintain its 2016 lead and command 92% of the market in 2026. A substantial amount of growth in that market is attributed to the rapid uptake of Galderma’sEpiduo (benzoyl peroxide and adapalene) for moderate patients and the continued success of isotretinoin. The anticipated launches of AOBiome’s B244 and Novan’s SB204 will add new molecular entities to the acne market for the first time in approximately 30 years. Paratek’s and Allergan’s Seysara, Foamix Pharmaceuticals’ FMX-101, and Cassiopea’sWinlevi are also expected to launch during the forecast period. Together, these late-stage pipeline products are expected to add approximately $956M in sales to the acne market in 2026.

The report Acne Vulgaris: Opportunity Analysis and Forecasts to 2026, provides overview of acne vulgaris, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

Key highlights of the report -

  • The greatest driver of growth in the global acne market will be the launches of five pipeline therapies during the forecast period. The entry of these anticipated drugs with novel mechanisms of action, including AOBiome’s B244, will be subject to rapid uptake.
  • The appreciation of compliance as a major factor that contributes to the success or failure of treatments, thus affecting sales. Galderma launched the TAP program to improve compliance of its key product, Epiduo. Increased patient and provider awareness will also help increase patient share of many marketed therapies during the forecast period.
Companies mentioned in this report: Allergan, Almirall, AndroScience, AOBiome, Astellas, Bayer, Botanix Pharmaceuticals, Braintree Laboratories , CassiopeaSpA, Celtaxys, Common Pharma, CutaneaLife Sciences, Dermira, Dow Pharma, Elorac Inc., Foamix Pharmaceuticals, Galderma, GSK, GuilianiSpA, Guthy-Renker, Medicis Pharmaceutical, Melinta Therapeutics, Mimetica, Novan, Novartis, Paratek, Photocure, Roche, Sanofi, SignumDermalogix, Stiefel Laboratories, Sun Pharmaceutical, Taro Pharmaceutical Industries, Valeant, Vyome Biosciences, XBiotech

Scope
  • Overview of acne vulgaris, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Annualized acne therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2016 and forecast for ten years to 2026.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the acne therapeutics market.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global acne therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy

The report will enable you to -
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
  • Develop business strategies by understanding the trends shaping and driving the global acne therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global acne therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global acne therapeutics market from 2016-2026.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Acne Vulgaris: Executive Summary
2.1 The US Acne Pharmaceutical Market Expected to Drive Moderate Global Growth between 2016 and 2026
2.2 Pharmaceutical Giants Revisiting the Acne Arena, Deploying Notable R&D Strategies to Attain Market Share
2.3 Innovative Products in Acne Should Focus on Cost-Effectiveness, Potential to Improve Compliance
2.4 Acne Market to Experience a Period of Investment in Research
2.5 The Late-Stage Pipeline Renews Hope for New and Novel Therapies That Can Further Challenge the Established Acne Landscape
2.6 What Do Physicians Think?
3 Introduction
3.1 Catalyst
3.2 Related Reports
3.3 Upcoming Related Reports
4 Disease Overview
4.1 Etiology and Pathophysiology
4.1.1 Etiology
4.1.2 Pathophysiology
4.2 Classification or Staging Systems
4.3 Symptoms
4.4 Prognosis
4.5 Quality of Life
5 Epidemiology
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.3.1 US
5.3.2 5EU
5.3.3 Japan
5.4 Forecast Methodology
5.4.1 Sources
5.4.2 Forecast Assumptions and Methods
5.5 Epidemiological Forecast for Acne Vulgaris (2016-2026)
5.5.1 Total Prevalent Cases of Acne Vulgaris
5.5.2 Diagnosed Prevalent Cases of Acne Vulgaris
5.5.3 Age-Specific Diagnosed Prevalent Cases of Acne Vulgaris
5.5.4 Sex-Specific Diagnosed Prevalent Cases of Acne Vulgaris
5.5.5 Diagnosed Prevalent Cases of Acne Vulgaris by Severity
5.6 Discussion
5.6.1 Epidemiological Forecast Insight
5.6.2 Limitations of Analysis
5.6.3 Strengths of Analysis
6 Current Treatment Options
6.1 Overview
6.2 Treatment Guidelines and Leading Prescribed Drugs
6.3 Tretinoin (numerous)
6.3.1 Overview
6.3.2 Efficacy
6.3.3 Safety
6.3.4 SWOT Analysis
6.4 Isotretinoin (numerous)
6.4.1 Overview
6.4.2 icacy
6.4.3 Safety
6.4.4 SWOT Analysis
6.5 Adapalene (numerous)
6.5.1 Overview
6.5.2 Efficacy
6.5.3 Safety
6.5.4 SWOT Analysis
6.6 Benzoyl Peroxide (numerous)
6.6.1 Overview
6.6.2 Efficacy
6.6.3 Safety
6.6.4 SWOT Analysis
6.7 Azelaic Acid (numerous)
6.7.1 Overview
6.7.2 Efficacy
6.7.3 Safety
6.7.4 SWOT Analysis
6.8 Hormonal Therapy (numerous)
6.8.1 Overview
6.8.2 Efficacy
6.8.3 Safety
6.8.4 SWOT Analysis
6.9 Epiduo
6.9.1 Overview
6.9.2 Efficacy
6.9.3 Safety
6.9.4 SWOT Analysis
6.10 Tretinoin and Clindamycin Phosphate (numerous)
6.10.1 Overview
6.10.2 Efficacy
6.10.3 Safety
6.10.4 SWOT Analysis
6.11 Benzoyl Peroxide and Clindamycin (numerous)
6.11.1 Overview
6.11.2 Efficacy
6.11.3 Safety
6.11.4 SWOT Analysis
6.12 Benzoyl Peroxide and Erythromycin (numerous)
6.12.1 Overview
6.12.2 Efficacy
6.12.3 Safety
6.12.4 SWOT Analysis
6.13 Minor Treatment Options
7 Unmet Needs and Opportunity Assessment
7.1 Overview
7.2 Improved Compliance
7.2.1 Unmet Need
7.2.2 Gap Analysis
7.2.3 Opportunity
7.3 Increased Patient and Caregiver Awareness
7.3.1 Unmet Need
7.3.2 Gap Analysis
7.3.3 Opportunity
7.4 Cost-Prohibitive Products
7.4.1 Unmet Need
7.4.2 Gap Analysis
7.4.3 Opportunity
7.5 Non-teratogenic Treatment Options for Female Acne Patients of Childbearing Age
7.5.1 Unmet Need
7.5.2 Gap Analysis
7.5.3 Opportunity
8 R&D Strategies
8.1 Overview
8.1.1 Reformulation Strategies
8.1.2 M&A in the Dermatology Market
8.1.3 New Mechanisms of Action
8.2 Clinical Trials Design
8.2.1 Current Clinical Trial Design
8.2.2 Limitations of Current Clinical Trial Design
8.2.3 Future Outlook in Acne Clinical Trial Design
9 Pipeline Assessment
9.1 Promising Drugs in Late-Stage Clinical Development
9.2 B244
9.2.1 Overview
9.2.2 Efficacy
9.2.3 Safety
9.2.4 SWOT Analysis
9.3 FMX-101
9.3.1 Overview
9.3.2 Efficacy
9.3.3 Safety
9.3.4 SWOT Analysis
9.4 Seysara (Sarecycline)
9.4.1 Overview
9.4.2 Efficacy
9.4.3 Safety
9.4.4 SWOT Analysis
9.5 SB204
9.5.1 Overview
9.5.2 Efficacy
9.5.3 Safety
9.5.4 SWOT Analysis
9.6 Winlevi
9.6.1 Overview
9.6.2 Efficacy
9.6.3 Safety
9.6.4 SWOT Analysis
9.7 Other Phase III Candidates
9.7.1 Olumacostat Glasaretil
9.8 Innovative Early-Stage Approaches
9.8.1 Overview
9.8.2 Biologics
9.8.3 Antibiotics
9.8.4 Small Molecules
10 Pipeline Valuation Analysis
10.1 Clinical Benchmark of Key Pipeline Drugs
10.2 Commercial Benchmark of Key Pipeline Drugs
10.3 Competitive Assessment
10.4 Top-Line 10-Year Forecast
10.4.1 US
10.4.2 5EU
10.4.3 Japan
11 Appendix
11.1 Bibliography
11.2 Abbreviations
11.3 Methodology
11.3.1 Forecasting Methodology
11.3.2 Diagnosed Patients
11.3.3 Percent Drug-Treated Patients
11.3.4 Drugs Included in Each Therapeutic Class
11.3.5 Launch Dates
11.3.6 General Pricing Assumptions
11.3.7 Individual Drug Assumptions
11.3.8 Pricing of Pipeline Agents
11.4 Primary Research - KOLs Interviewed for This Report
11.5 Primary Research - Prescriber Survey
11.6 About the Authors
11.6.1 Analyst
11.6.2 Associate Analyst
11.6.3 Therapy Area Director
11.6.4 Epidemiologist
11.6.5 Epidemiology Reviewers
11.6.6 Global Director of Therapy Analysis and Epidemiology
11.6.7 Global Head and EVP of Healthcare Operations and Strategy
11.7 About GlobalData
11.8 Contact Us
11.9 Disclaimer
1.1 List of Tables
Table 1: Acne Vulgaris: Key Metrics in the 7MM
Table 2: Clinical Classification of Acne According to Severity
Table 3: Risk Factors and Comorbidities for Diagnosed Prevalent Cases of Acne Vulgaris
Table 4: 7MM, Total Prevalent Cases of Acne Vulgaris, Ages 7-60 Years, Both Sexes, N, Select Years 2016-2026
Table 5: 7MM, Diagnosed Prevalent Cases of Acne Vulgaris, Ages 7-60 Years, Both Sexes, N, Select Years 2016-2026
Table 6: Treatment Guidelines for Acne Vulgaris
Table 7: Commonly Used Treatments for the Management of Acne
Table 8: Product Profile - Tretinoin
Table 9: Tretinoin SWOT Analysis, 2018
Table 10: Product Profile - Isotretinoin
Table 11: Isotretinoin SWOT Analysis, 2018
Table 12: Product Profile - Adapalene
Table 13: Adapalene SWOT Analysis, 2018
Table 14: Product Profile - Benzoyl Peroxide
Table 15: Benzoyl Peroxide SWOT Analysis, 2018
Table 16: Product Profile - Azelaic Acid
Table 17: Azelaic Acid SWOT Analysis, 2018
Table 18: Product Profile - Hormonal Therapy
Table 19: Hormonal Therapy SWOT Analysis, 2018
Table 20: Product Profile - Epiduo
Table 21: Epiduo SWOT Analysis, 2018
Table 22: Product Profile - Tretinoin and Clindamycin Phosphate
Table 23: Tretinoin and Clindamycin Phosphate SWOT Analysis, 2018
Table 24: Product Profile - Benzoyl Peroxide and Clindamycin Phosphate
Table 25: Benzoyl Peroxide and Clindamycin Phosphate SWOT Analysis, 2018
Table 26: Product Profile - Benzoyl Peroxide and Erythromycin
Table 27: Benzoyl Peroxide and Erythromycin SWOT Analysis, 2018
Table 28: Summary of Minor Therapeutic Classes, 2018
Table 29: Acne Vulgaris - Late-Stage Pipeline, 2017
Table 30: Product Profile - B244
Table 31: B244 SWOT Analysis, 2018
Table 32: Product Profile - FMX-101
Table 33: FMX-101 SWOT Analysis, 2018
Table 36: Product Profile - Seysara
Table 37: Seysara SWOT Analysis, 2018
Table 38: Product Profile - SB204
Table 39: SB204 SWOT Analysis, 2018
Table 40: Product Profile - Winlevi
Table 41: Winlevi SWOT Analysis, 2018
Table 42: Innovative Early-Stage Approaches for Acne Vulgaris, 2018
Table 43: Clinical Benchmark of Key Pipeline Drugs - Tetracycline-Derived Antibiotics
Table 44: Clinical Benchmark of Key Pipeline Drugs - Androgen Suppressors
Table 45: Commercial Benchmark of Key Pipeline Drugs - Tetracycline-Derived Antibiotics
Table 46: Commercial Benchmark of Key Pipeline Drugs - Androgen Suppressors
Table 47: Key Events Impacting Sales for Acne Vulgaris, 2016-2026
Table 48: Acne Vulgaris Market - Global Drivers and Barriers, 2016-2026
Table 49: Key Projected Launch Dates for Acne Vulgaris
Table 50: High-Prescribing Physicians (Non-KOLs) Surveyed, By Country
1.2 List of Figures
Figure 1: Global Sales Forecast by Country for Acne Vulgaris in 2016 and 2026
Figure 2: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the Standard of Care (SOC), Acne Vulgaris
Figure 3: Pathogenesis Pathway of Acne
Figure 4: Major Drug Targets for Acne Treatment
Figure 5: Symptomatic Representations of Acne
Figure 6: Age-Standardized Total Prevalence of Acne Vulgaris, Ages 7-60 Years, 2016
Figure 7: Age-Standardized Diagnosed Prevalence of Acne Vulgaris, Ages 7-60 Years, 2016
Figure 8: Sources Used and Not Used to Forecast Total Prevalent Cases of Acne Vulgaris
Figure 9: Sources Used to Forecast Diagnosed Prevalent Cases of Acne Vulgaris
Figure 10: Sources Used and Not Used to Forecast Diagnosed Prevalent Cases of Acne Vulgaris by Severity
Figure 11: 7MM, Age-Specific Diagnosed Prevalent Cases of Acne Vulgaris, Both Sexes, 2016
Figure 12: 7MM, Sex-Specific Diagnosed Prevalent Cases of Acne Vulgaris, Ages 7-60 Years, 2016
Figure 13: 7MM, Diagnosed Prevalent Cases of Acne Vulgaris, Ages 7-17 Years, Both Sexes, N, 2016
Figure 14: 7MM, Diagnosed Prevalent Cases of Acne Vulgaris, Ages 18-60 Years, Both Sexes, 2016
Figure 15: Acne Treatment Algorithm
Figure 16: Unmet Need and Opportunity in Acne Vulgaris, 2018
Figure 17: Overview of the Development Pipeline in Acne Vulgaris
Figure 18: Key Phase IIb/III Trials for the Promising Pipeline Agents that GlobalData Expects be Licensed for Acne Vulgaris in the 7MM During the Forecast Period
Figure 19: Competitive Assessment of the Marketed and Pipeline Tetracycline-Derived Antibiotics
Figure 20: Competitive Assessment of the Marketed and Pipeline Androgen Suppressors
Figure 21: Global (7MM) Sales Forecast by Country for Acne Vulgaris in 2016 and 2026

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report